



By Carolyn Gretton

### ► PHARMACEUTICAL POOL

#### Dr. Janet **HAMMOND** ROCHE STRENGTHENS TRANSLATIONAL MEDICINE LEADERSHIP



Roche has appointed Janet Hammond, M.D., Ph.D., VP, translational medicine – virology in pharmaceutical research and early development (pRED).

Dr. Hammond joins Roche from Valeant Pharmaceuticals International, where she served as chief medical officer and senior VP of global medical affairs. She received an M.D. and a Ph.D. from the University of Cape Town in South Africa, as well as an ScM in clinical investigation from Johns Hopkins University.

#### Trevor **SMITH**

##### TAKEDA SUBSIDIARY NAMES CEO



Japan's Takeda Pharmaceutical Co. Ltd. has promoted Trevor Smith to CEO of Takeda Pharmaceuticals Europe Ltd. (TPEU), Takeda's London-based subsidiary for oversight of pan-European sales and marketing.

Mr. Smith, who previously served as Takeda's VP, international strategy, has more than 30 years of pharmaceutical experience. He succeeds retiring TPEU CEO Erich Brunn, Ph.D.

### ► BIOTECHNOLOGY POOL

#### Dr. Jonathan **LEFF**

##### KALOBIOUS NAMES MEDICAL CHIEF



KaloBios Pharmaceuticals has appointed Jonathan Leff, M.D., chief medical officer. Dr. Leff previously served as VP and chief medical officer of Halozyne Therapeutics. He received an M.D. from the University of Pennsylvania School of Medicine.

KaloBios is a private company developing a portfolio of patient-targeted monoclonal antibodies designed to treat difficult-to-treat diseases.

### ► BIOPHARMACEUTICAL POOL

#### Dr. Jay **BARTH**

#### Dr. Robert **SPIEGEL**

##### PTC THERAPEUTICS ANNOUNCES EXECUTIVE CHANGES

PTC Therapeutics, a biopharmaceutical company



focused on the discovery, development, and commercialization of orally administered small-molecule drugs, has strengthened its executive team in anticipation of moving its lead compound, ataluren, toward regulatory filings.



PTC has promoted Jay Barth, M.D., to VP of clinical development, responsible for leading all clinical development programs for ataluren. Dr. Barth received an M.D. from the University of Pennsylvania School of Medicine.

Robert Spiegel, M.D., has joined PTC as chief medical officer, from the same role at Schering-Plough. Dr. Spiegel received an M.D. from the University of Pennsylvania School of Medicine.

#### Joshua **HAMERMESH**

##### INFINITY PHARMACEUTICALS NAMES BUSINESS DEVELOPMENT VP

Infinity Pharmaceuticals, a biopharmaceutical company seeking to discover, develop, and deliver medicines for difficult-to-treat diseases, has named Joshua Hamermesh VP, business and corporate development. Mr. Hamermesh most recently served as senior VP, strategy and corporate development, for Pervasis Therapeutic. He received an MBA from Harvard Business School.



#### Dr. Pablo **LAPUERTA**

##### LEXICON TAPS FORMER BRISTOL-MYERS SQUIBB EXECUTIVE AS MEDICAL CHIEF



Lexicon Pharmaceuticals has appointed Pablo Lapuerta, M.D., chief medical officer, responsible for directing clinical development of the biopharmaceutical company's drug candidates from Phase II proof-of-concept through Phase III and approval.

Dr. Lapuerta has 15 years of pharmaceutical industry experience in a variety of leadership roles. He most recently served as VP at Bristol-Myers Squibb responsible for global development of an Alzheimer's disease drug candidate. Dr. Lapuerta has an M.D. from Harvard Medical School.

### ► DIAGNOSTIC POOL

#### John **KRAYACICH**

##### EXACT SCIENCES ANNOUNCES MARKETING VP

Exact Sciences, a molecular diagnostics company focused on the early detection and prevention of colorectal cancer, has appointed John Krayacich senior VP, sales and marketing. Mr. Krayacich brings

to Exact more than 20 years of leadership experience and was most recently president and CEO of two start-up biotechnology companies, Ambrose Pharmaceuticals and Marinus Pharmaceuticals. He received a master's degree and an MBA from the University of Western Ontario.



#### Robert **YATES**

##### ROCHE DIAGNOSTICS PROMOTES APPLIED SCIENCE HEAD

Roche Diagnostics has promoted Robert Yates to head of Roche Applied Science, from global head of business development and licensing. Mr. Yates succeeds Manfred Baier, who is retiring.



### ► AGENCY POOL

#### Danielle **BENJOYA**

#### Meghan **MULHERN**

#### Craig **TAYLOR**

#### Dr. Gregory **THOMPSON**

##### STAFF PROMOTIONS AT ABELSONTAYLOR



Independent healthcare advertising agency AbelsonTaylor has made a number of promotions across its account services team.




Danielle Benjoya has been promoted to account executive, from account coordinator. Ms. Benjoya is currently working on a hormone replacement therapy product.



Meghan Mulhern has been promoted to account executive, from account coordinator. Ms. Mulhern is currently working on endocrinology products.



Craig Taylor has been promoted to account executive, from account coordinator. Mr. Taylor is currently working on women's health products.



Gregory Thompson, M.D., has been promoted to VP, medical director, in charge of scientific strategy, from his previous role as medical director. Dr. Thompson has expanded his role as industry liaison and client consultant. He received an M.D. from the West Virginia University School of Medicine.

#### Joy **CATANIA-HOGAN**

##### NATREL EXPANDS CREATIVE TEAM

Independent healthcare advertising agency Natrel Communications has named Joy Catania-Hogan



senior editor. Ms. Catania-Hogan has served as a freelance medical editor at a number of agencies over the past 10 years.

## Amber EDWARDS

### DRAFTFCB ADDS VP



Amber Edwards has joined Draftfcb Healthcare as executive VP, group management director, leading the agency's direct-to-consumer healthcare accounts, including Novartis, Merck, Lilly, and Amgen. Ms. Edwards brings more than 14 years of experience in health and pharmaceutical markets, most recently overseeing DTC, CRM, and digital channels for two brands with J Walter Thompson.

## Tom FERRARA

## Allison GHEGAN

## Joe MADSEN

## Valerie SHANE

## Dan SIMON

## Michelle VARGA

### CENTRON EXPANDS CREATIVE, STRATEGIC STAFF



Medical communications company Centron, part of the HealthSTAR Communications network, has announced a number of significant staff additions.

Tom Ferrara has joined Centron as senior VP, associate creative director. Mr. Ferrara was previously creative director with Beacon Healthcare.



Allison Ghegan has joined Centron as account executive. Joe Madsen has been named art director. Mr. Madsen was formerly a freelance art director.

Valerie Shane has been named senior VP, associate creative director. Ms. Shane joins Centron from Saatchi & Saatchi Healthcare Advertising, where she was VP, group account director. Dan Simon has been appointed executive VP, creative director. Mr. Simon was most recently senior VP, group director for LyonHeart/LLNS.

Michelle Varga has been named medical editor. Ms. Varga was previously a freelance medical editor.

## Laura FUSCO

### WCG NAMES FORMER GHG VP CREATIVE PRACTICE LEAD

WCG, an independent agency partnering with



clients in the healthcare, consumer products, and technology industries, has appointed Laura Fusco leader of its creative practice, working out of its New York office. Ms. Fusco joins WCG from Grey Healthcare Group (GHG), a division of WPP, where she was most recently executive VP, franchise chemist on the Johnson & Johnson team chemistry consolidation.

## Michele MCHUGH-MAZZATTA

### GLAXOSMITHKLINE VETERAN JOINS QUANTUMMETHOD AS PARTNER



QuantumMethod (QM), a life-sciences branding and communications firm, has appointed Michele McHugh-Mazzatta partner, tasked with managing the agency's East Coast operations.

Before joining QM, Ms. McHugh-Mazzatta spent two decades with GlaxoSmithKline, building industry expertise in cross-functional areas such as sales, marketing, contract management, internal trade, and sales operations, and subsequently founded her own consulting firm, Four M Group.

## CONSULTING POOL

## Terry BURNSIDE

### NEW MANAGEMENT CONSULTANT AT D2 PHARMA



D2 Pharma Consulting has appointed Terry Burnside senior consultant, executive management/strategic planning. Mr. Burnside was previously president/general manager of Cardinal Health's Medicine Shoppe International subsidiary.

## Melissa CLARK

## Dr. Emily WALSH

### HALLORAN EXPANDS CONSULTING TEAM



Halloran Consulting Group has made two staff additions as part of an ongoing effort to substantially increase Halloran's alliance management, translational program management, and regulatory strategy offerings.



Melissa Clark has joined Halloran as a senior consultant. Ms. Clark previously led the corporate regulatory affairs department at Boston Scientific. She holds an M.S. in human nutrition from the University of Bridgeport.

Emily Walsh, Ph.D., has been named a principal consultant. Dr. Walsh has broad expertise in managing drug discovery and clinical programs across

a breadth of indications, most recently as CEO and founder of Tremont Therapeutics. She earned a Ph.D. from the University of California, San Francisco.

## Alex CONTRERAS

## Sanjay JOSHI

## Bill SUDLOW

## Ashish VAZIRANI

### NEW PRINCIPALS AT ZS ASSOCIATES



Global management consulting firm ZS Associates has hired four principals to provide expertise and leadership in areas targeted for firm-wide growth and expansion of key client services.



Alex Contreras has been named principal and member of the leadership team in ZS Associates' business technology group, based in the firm's Los Angeles office. Mr. Contreras was previously a director with the technology risk practice at Deloitte. He holds a master's degree in accounting and information systems from Arizona State University.



ZS Associates has appointed Sanjay Joshi managing principal of its global operations practice, based in the company's New York office. Mr. Joshi is a 20-year veteran in management consulting and business and technology outsourcing consulting, most recently serving as chief executive of Wipro Consulting and vice chairman of Wipro's business process outsourcing division. He received an MBA from the Kellogg School of Management at Northwestern University and a master's degree in computer science from Pennsylvania State University.

Bill Sudlow has joined ZS Associates as chief technology officer and principal in charge of the firm's software development group. Mr. Sudlow is based at the company's global headquarters in Evanston, Ill.

Mr. Sudlow's 25 years of software product development and management experience include stints as VP of product development at independent software vendors Intuit and Xactly, as well as numerous management positions at Hewlett-Packard. He received an MBA in marketing from Santa Clara University and a master's degree in electrical engineering from Stanford University.

Ashish Vazirani has been named principal and leader of ZS Associates' high-tech practice, based in the San Mateo, Calif., office. Mr. Vazirani was most recently a senior VP with MarketBridge. He earned a double master's degree in management and engineering from Northwestern University's Kellogg School of Management and McCormick School of Engineering.

## ► SERVICE POOL

### Dr. Kenneth CARTER

#### NOBLE LIFE SCIENCES APPOINTS CEO



Noble Life Sciences, a provider of pre-clinical research services to the pharmaceutical and biotechnology industries, has named Kenneth Carter, Ph.D., president and CEO.

Dr. Carter was previously a consultant to the life-sciences industry and served on an interim basis as Noble's president.

### Mark DEGATANO

#### IMPACTRX SELECTS MERCK VETERAN AS CLIENT SERVICES VP



Pharmaceutical market research company ImpactRx has named Mark Degatano senior VP, client services operations, leading the advanced analytics, custom market research, and syndicated analytic support teams. Mr. Degatano joins ImpactRx after 24 years at Merck, where he was most recently VP, U.S. human health customer insights. He received an M.A. in statistics from Boston University.

### Howard DRAZNER

#### ESSRX NAMES PRESIDENT



ESSRX has appointed Howard Drazner president, succeeding Doug Mack, who remains CEO. Mr. Drazner was previously senior VP at PDI and president of PDI's Pharmakon division.

ESSRX is the parent company of satellite broadcast services provider Advantage Broadcast Solutions; AV Solutions, a provider of audio-visual equipment rentals to pharmaceutical companies; and Total Health Rewards.

### Dawn DUGGAN

#### A10 CLINICAL SOLUTIONS APPOINTS STRATEGIC DIRECTOR



Dawn Duggan has joined A10 Clinical Solutions as director of strategic clinical solutions, responsible for strategically growing A10's presence within the northeastern U.S. pharmaceutical and biotechnology hub.

Ms. Duggan also plays an integral role in A10's involvement with Diversity Alliance for Science (DA4S), a nonprofit organization co-founded by A10 President and CEO Leah Brown. Ms. Duggan was most recently an operations manager at Integrated Resources.

A10 Clinical Solutions specializes in clinical research and on-site preventive care health clinics for large pharmaceutical companies, government agencies, hospital systems, and corporate entities.

### Jack EDLER

#### EXCO INTOUCH TO EXPAND U.S. OPERATIONS



Exco InTouch, a provider of patient communication solutions for the pharmaceutical and healthcare sectors, has appointed Jack Edler senior director of business development. Mr. Edler's appointment is in conjunction with the move of Exco's U.S. operational headquarters to Cary, N.C., to enable the continued expansion of the company alongside the improvement of its client hosting facilities. Mr. Edler brings to Exco more than 20 years of experience, most recently as senior director, business development at Perceptive Informatics.

### Dr. David FRYBURG

#### John TAGLIAMONTE SELVENTA STRENGTHENS LEADERSHIP TEAM



Selventa, a provider of scientific consulting services, licensed software products, and strategic partnerships to life-sciences companies, has added two executives to its leadership roster.



David Fryburg, M.D., has joined Selventa as chief medical officer, responsible for contributing to the company's scientific strategy, particularly through his expertise in translational medicine and biomarker development. Dr. Fryburg was most recently Pfizer's executive director and global translational medicine lead for cardiovascular, metabolic, and endocrine diseases. He received an M.D. from Albert Einstein College of Medicine of Yeshiva University.

John Tagliamonte has been appointed senior VP of corporate development, with responsibility for promoting and establishing strategic partnerships with global pharmaceutical and biotechnology. Mr. Tagliamonte was previously VP, business development for Anchor Therapeutics. He received an MBA from Boston College.

### Shaliya KHAN

#### Jac LEE

#### Dave PHILLIPS

#### Ed SLEEPER

#### CLEARPOINT MAKES ADDITIONS, PROMOTIONS



ClearPoint, a global provider of interactive health education services to the life-sciences industry, has unveiled a number of staff changes.

Shaliya Khan has been promoted to senior manager, global marketing and sales, from her earlier business development role. Ms. Khan is spearheading the company's marketing,



branding and thought-leadership initiatives and is based in ClearPoint's India office.



Jac Lee has joined ClearPoint's U.K. office as U.K. business development director to expand the company's presence in the Europe, Middle East, and Africa (EMEA) market. Mr. Lee has worked in medical communications for more than 15 years and has been associated with leading companies across the United Kingdom, Europe, and the United States.



Dave Phillips has been named director of technology. Before joining ClearPoint, Mr. Phillips led the worldwide support organization at OutStart.

Ed Sleeper has been appointed director of compliance for ClearPoint. Mr. Sleeper's previous experience includes stints as director of CME operations for Medscape and director of operations for Axiom Professional Health Learning.

## ► TECHNOLOGY POOL

### Jim BAKER

#### CYTEL HIRES CLINICAL RESEARCH VP



Cytel, a provider of clinical trial design and implementation services and software, has named Jim Baker VP, clinical research services. Mr. Baker has almost three decades of experience in biopharmaceutical development, most recently as senior director of study standards implementation at Millennium: The Takeda Oncology Company.

### Dr. Jeffrey LITWIN

#### ERT SELECTS CHIEF EXECUTIVE



ERT, a global technology-driven provider of clinical services and customizable medical devices to biopharmaceutical and healthcare organizations, has promoted Jeffrey Litwin, M.D., to president and CEO. Joel Morganroth, M.D., who had served as interim president and CEO, continues as chief scientific officer.

Dr. Litwin joined ERT in 2000 as senior VP and chief medical officer and has served as executive VP and chief medical officer since late 2005. A board-certified cardiologist, Dr. Litwin also serves on the DIA Annual Meeting planning committee and the board of directors of the Metrics Champion Consortium. <sup>PV</sup>



USE YOUR QR CODE READER  
OR GO TO  
[bit.ly/PV0611-Pool](http://bit.ly/PV0611-Pool)

